Pipeline
Decoding the ECM to transform the therapeutic landscape
We are developing a portfolio of proprietary and partnered programmes in fibrosis, inflammation and solid tumours using our pioneering human extracellular matrix platform.
Pipeline
Assets/Targets
Indication(s)
Target validation
Discovery
Preclinical
IND
Commercial rights
EGTX003
Inflammation/fibrosis
EGTX004
Solid tumours and advanced fibrosis
EGTX006
Advanced fibrosis
Confidential
Advanced MASH fibrosis
Confidential
FSCD
Assets/Targets
EGTX003
Indication(s)
Inflammation/ fibrosis
Commercial rights
Assets/Targets
EGTX004
Indication(s)
Solid tumours and advanced fibrosis
Commercial rights
Assets/Targets
EGTX006
Indication(s)
Advanced Fibrosis
Commercial rights
Assets/Targets
Confidential
Indication(s)
Advanced MASH fibrosis
Commercial rights
Assets/Targets
Confidential
Indication(s)
FSCD
Commercial rights
MASH: Metabolic Associated SteatoHepatitis
FCSD: Fibrostenotic Crohn’s Disease
Our Therapeutic Targets
Structural
By hooking onto ECM fibres, structural anchoring targets steer treatments directly into the diseased microenvironment to halt or even reverse progression.
Bioactive
Bioactive proteins are molecular ‘switches’ that tug at the ECM’s structure, sending signals that influence inflammation, repair, and disease activity.
Cellular
Cellular targets are diseased or dysregulated cells embedded in the ECM that can be identified, tracked, and treated.
